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Abstract
Background: Despite approvals of immune checkpoint inhibitors in both small cell and non-small cell lung
cancers, the role of immunotherapy in large cell neuroendocrine carcinoma (LCNEC) in lung is undefined. Methods:
Using the National Cancer Database (NCDB), Stage IV lung LCNEC cases diagnosed from 2014 to 2016 were
analyzed. Information regarding cancer treatment was limited to first course of therapy, including surgery for primary
lesion, radiation, chemotherapy, and immunotherapy. Survival analysis was performed using Kaplan-Meier curves
and Log-rank tests. Cox proportional hazard model was used for multivariate analysis. Results: Among 661 eligible
cases, 37 patients were treated with immunotherapy. No significant association between use of immunotherapy and
clinical demographics was observed except for use of chemotherapy (p=0.0008). Chemotherapy was administered in
34 (92%) and 406 (65%) in immunotherapy and non-immunotherapy groups, respectively. Use of immunotherapy
was associated with improved overall survival (Log-rank p=0.0018). Landmark analysis in the immunotherapy group
showed 12 and 18-month survivals of 34.0% and 29.1%, respectively, whereas those in the non-immunotherapy group
were 24.1% and 15.0%, respectively. Multivariate analysis demonstrated that female sex (HR=0.79, p=0.0063), liver
metastases (HR=0.75, p=.0392), surgery (HR= 0.50, p<0.0001) use of chemotherapy (HR= 0.44, p<0.0001), and use of
immunotherapy (HR=0.64, p=0.0164) had statistical significance. Propensity score matching in overall survival analysis
showed a nonsignificant trend (p=0.0733) in favor of immunotherapy treatment. Conclusion: This retrospective study
using NCDB suggests that use of immunotherapy may improve survival of LCNEC patients.
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Introduction
Large cell neuroendocrine carcinoma (LCNEC)
is a relatively rare histologic subtype, accounting for
approximately 3% of lung cancer cases (Fasano et
al., 2015, Rekhtman, 2010). It has been described in
recent decades since Travis et al. originally described
it in the early 1990s (Travis, et al., 1991). Despite its
neuroendocrine features, it was initially classified as a
variant of large cell carcinoma by the 2004 World Health
Organization (WHO). The current 2015 version of WHO
lists it in a group of neuroendocrine neoplasms along
with typical carcinoid, atypical carcinoid, and small cell
carcinoma (Travis et al., 2015).
Due to its sparsity of cases and difficulty in diagnosis
with small biopsy samples, standard systemic therapy
for advanced stage has not been well established. To our
knowledge, no prospective, randomized study comparing
multiple systemic regiments has been reported in the
literature. Limited literature with retrospective studies,
case reviews, and single arm prospective trials suggest that

regimens used for small cell lung cancers (i.e., platinum
plus etoposide) are superior to those used for non-small
cell lung cancer (i.e., platinum plus taxane) and result in
improved patient outcomes for stage IV cancers, as well
as for early stages when the chemotherapy is given as
adjuvant therapy (Sun et al., 2012, Zhang et al., 2020, Le
Treut et al., 2013, Niho et al., 2013) although contradictory
reports exist (Derks et al., 2017).
Recent progress in the development of immune
checkpoint inhibitors has dramatically changed survival
outcomes and disease management for lung cancer.
Several agents have been approved as monotherapy
or are used in combination with chemotherapy agents
for a number of human cancer types. Pembrolizumab,
nivolumab, atezolizumab, and durvalumab are approved
by the FDA for the treatment of advanced non-small cell
lung cancer (NSCLC). Treatment with atezolizumab or
durvalumab, a monoclonal antibody directed against
programmed cell death ligand 1 (PDL1), resulted in
improved overall survival of patients with extensive stage
small cell lung cancer (ES-SCLC) when combined with
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first-line chemotherapy (Horn et al., 2018, Paz-Ares et al.,
2019). Although these agents are currently investigated
in early stage settings of SCLC and NSCLC, rare cancer
subtypes such as LCNEC may not be investigated soon due
to paucity of the disease. It seems unlikely that controlled
randomized studies will be conducted specifically for
LCNEC for the next few decades.
Because of limitations in retrospective case series
and lack of potential for prospective clinical trials
for rare disease such as LCNEC, cancer researchers
commonly use large databases to analyze rare cancer
types. Although there are some limitations, this approach
allows assessment of prognosis and impact of therapeutic
interventions across a larger patient population. Using
the National Cancer database (NCDB), we investigated
whether the use of immunotherapeutic agents influences
overall survival in patients with stage IV LCNEC.

Materials and Methods
NCDB
The National Cancer Data Base (NCDB) is a joint
project of the Commission on Cancer (CoC) of the
American College of Surgeons and the American Cancer
Society. The CoC’s NCDB and the hospitals participating
in the CoC NCDB are the source of the de-identified data
used herein; they have not verified and are not responsible
for the statistical validity of the data analysis or the
conclusions derived by the authors. The data is considered
as hospital-based rather than population-based.
After obtaining approval by CoC, access to information
of deidentified cases with stage IV NSCLC was granted
in October 2019. A total of 101,169 adult cases diagnosed
between 2014 and 2016 at the CoC participating institution
in the United States were screened for the current study.
Eligible cases must have the diagnostic ICD-O-3 code for
LCNEC (8013/3) and have survived for at least one month
(Figure 1). Presence or absence of IO (immunotherapy)
as the first course of therapy was available. They were
assigned into IO positive vs. negative groups. Information
regarding name, regimen, dose, dosing frequency of IO
was not available.
Available background characteristics included age

101,169

1,164

661

37

(<70 vs. 70+), sex (male vs. female), race (white vs.
others), type of institution (academic vs. non-academic),
presence of insurance, Charlson-Deyo comorbidity score
(0-1 vs. 2-3), presence of brain/liver metastases, use of
external beam radiation, use of multiagent chemotherapy
in first course of therapy. Reporting any cell with less than
10 cases were prohibited according to agreement with
CoC and NCDB.
Overall survival data was available according to
IO status in first course of therapy. Progression-free,
time-to-progression, or other survival data were not
available.
Statistics
Relationships between clinical characteristics and
use of IO were determined by chi-square tests. Survival
analysis was conducted using Kaplan-Meier and Logrank
methods. A p-value of less than 0.05 on a two-tailed
statistical analysis was considered significant. Univariate
and multivariate Cox proportional hazard analyses were
performed using JMP version 14 (SAS Institute, Cary, NC,
USA). Propensity score matching analysis included all the
variables listed in Table 1 and was performed according to
XLSTAT software guideline (Rosenbaum, 1989).
This is a hospital-based study that involves no
identifiable information for individuals throughout the
analyses. This study was reviewed by the institutional
review board at Parkview Health and was designated
exempt from human subject research.

Results
Patient characteristics
A total of 661 patients with stage IV LCNEC diagnosed
between 2014 and 2016 met eligibility for this study (Table
1). Among those, 37 and 624 patients were assigned to IO
or non-IO group, respectively.
In the IO group, the majority of cases were categorized
as follows: less than age 70 (68%), male sex (62%), white,
insured (100%), treated at non-academic centers (54%),
Charlson-Deyo (CD) comorbidity score of 0-1, absence
of brain metastasis, absence of liver metastasis (73%),
absence of surgery (97%), and presence of chemotherapy.

Patients with any stage IV NSCLC diagnosed
and captured in the NCDB between 2014 and 2016

Large cell neuroendocrine carcinoma

Overall survival data available and OS ≥ 30days

Stage IV LCNEC with IO

624

Stage IV LCNEC without IO

Figure 1. Study Flow Diagram of Case Eligibility. NSCLC, non-small cell lung cancer; NCDB, National Cancer
Database; OS, overall survival; LCNEC, large cell neuroendocrine carcinoma; IO, immunotherapy.
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Table 1. Clinical Characteristics of Stage IV LCNEC
Patients with or without Immunotherapy
Immunotherapy

Total

Yes

No

37 (100%)

624 (100%)

661 (100%)

<70

25 (68%)

398 (64%)

423 (64%)

70+

12 (32%)

226 (36%)

238 (36%)

Male

23 (62%)

337 (54%)

360 (54%)

Female

14 (38%)

287 (46%)

301 (46%)

Total

P value

0.641

Sex
0.333

Race
37 (100%)

624 (100%)

661 (100%)

Others

0 (0%)

19 (3%)

19 (3%)

605 (97%)

642 (97%)

17 (46%)

201 (32%)

218 (33%)

Others

20 (54%)

423 (68%)

443 (67%)

37 (100%)

624 (100%)

661 (100%)

51 (69%)

11 (30%)

23 (11%)

Male

23 (62%)

25 (68%)

48 (65%)

Female

14 (38%)

12 (32%)

26 (35%)

37 (100%)

37 (100%)

74 (100%)

0.7438
1

0.084

0.541

37 (100%)

624 (100%)

661 (100%)

10 (27%)

170 (27%)

180 (27%)

27 (73%)

454 (73%)

481 (73%)

0 (0%)

0 (0%)

0 (0%)

37 (100%)

74 (100%)

Academic

17 (46%)

16 (43%)

33 (45%)

Others

20 (54%)

21 (57%)

41 (55%)

37 (100%)

37 (100%)

74 (100%)

0.1647

37 (100%)

37 (100%)

74 (100%)

0.2785
0.7965

Institution

Yes

10 (3%)

170 (6%)

180 (27%)

Brain metastasis

0.977

Liver metastasis

No

27 (97%)

454 (94%)

481 (73%)

0.43

0.8151

Charlson-Deyo score

0.127

Surgery for primary lesion

0.6263

37 (100%)

Yes and No

No

0.8017

Sex

0-1 and 2-3+

Yes

Yes

10 (27%)

11 (30%)

21 (28%)

No

27 (73%)

26 (70%)

53 (72%)

37 (100%)

37 (100%)

74 (100%)

0.3039

Yes

17 (46%)

16 (43%)

33 (45%)

0.8151

No

20 (54%)

21 (57%)

41 (55%)

37 (100%)

37 (100%)

74 (100%)

Surgery for primary lesion
Yes and No
Radiation

Radiation
17 (46%)
20 (54%)

324 (52%)
300 (48%)

341 (52%)

0.48

320 (48%)

Chemotherapy

Chemotherapy
Yes and No

26 (70%)

12 (32%)

Uninsured

Liver metastasis

No

25 (68%)

70+

0.281

Brain metastasis

Yes

<70

Age

Insurance status

Charlson-Deyo score

Yes and No

74 (100%)

Others

Academic

0-1 and 2-3+

37 (100%)

Race

Institution

P value

37 (100%)

Whites and Others

37 (100%)

Total

No

0.943

Insurance status
Uninsured

Immunotherapy
Yes
Total

Age

Whites and others

Table 2. Clinical Characteristics of Stage IV LCNEC
Patients with or without Immunotherapy: Propensity
Score Matched Cases

37 (100%)

624 (100%)

661 (100%)

0.0008

Yes and No

0.6433

Note: Due to NCDB agreement, cells with less than 10 cases in Race,
Charlson-Deyo score, Brain metastasis and Chemotherapy were
combined with other opposing cells.

Note: Due to NCDB agreement, cells with less than 10 cases in Race,
Charlson-Deyo score, Brain metastasis and Chemotherapy were
combined with other opposing cells

There was no significant association between the clinical
characteristics and presence/absence of IO except for use
of chemotherapy; more patients (92%) in the IO group

received chemotherapy than those in the non-IO group.
In the propensity matched analysis, all the variables were
matched and balanced. No significant correlation between

Figure 2. Overall Survival According to Use of Immunotherapy
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Table 3. Univariate and Multivariate Analysis in Original Cohort
Variable

Univariate
HR (95%CI)

P value

Multivariate
HR (95%CI)

P value

Age: <70/70+

0.75 (0.63-0.89)

0.0013

0.87 (0.73-1.05)

0.151

Sex: F/M

0.79 (0.67-0.93)

0.005

0.79 (0.67-0.94)

0.0063

Race: Other/W

0.78 (0.62-0.98)

0.0297

0.83 (0.65-1.05)

0.1199

Insurance: Other/Uninsured

0.88 (0.57-1.46)

0.6016

0.74 (0.47-1.23)

0.2318

Institution: Academic/Other

0.83 (0.69-0.98)

0.033

0.92 (0.76-1.11)

0.3896

Charlson-Deyo score: 0-1/2-3

0.79 (0.63-1.00)

0.047

0.84 (0.67-1.07)

0.1619

Brain metastasis: N/Y

0.95 (0.79-1.13)

0.5406

0.94 (0.77-1.16)

0.5829

Liver metastasis: N/Y

0.75 (0.63-0.90)

0.0026

0.81 (0.67-0.99)

0.0392

Surgery: Y/N

0.50 (0.32-0.73)

0.0001

0.46 (0.30-0.68)

<0.0001

Radiation: Y/N

0.91 (0.77-1.07)

0.248

0.98 (0.81-1.20)

0.8736

Chemotherapy: Y/N

0.44 (0.37-0.52)

<0.0001

0.44 (0.37-0.53)

<0.0001

Immunotherapy: Y/N

0.63 (0.42-0.91)

0.0112

0.64 (0.43-0.93)

0.0164

any variable and IO status was observed (Table 2). Due
to the restriction by CoC and NCDB, cells with less than
10 cases are not provided in Table 1 or 2.
Survival analysis
Univariate and multivariate analyses were conducted
for the original cohort. In the univariate analysis,
significantly improved survival was seen in young age,
female sex, non-white race, academic institution, CD score
of 0-1, absence of liver metastasis, use of surgery, use of
chemotherapy, and use of IO. Female sex, absence of liver
metastasis, use of surgery, use of chemotherapy, and use
of IO remained statistically significant in multivariate
analyses (Table 3). Kaplan-Meier and Logrank methods
demonstrated a statistically improved survival in the
original cohort (p= p=0.0018) and a non-significant trend
in propensity score matched cohort (p=0.0733) (Figure 2).

Discussion
LCNEC is a relatively rare and aggressive type of
lung cancer with abysmal prognosis that accounts for
3% of lung cancer with most patients being diagnosed in
advanced stages (Fasano et al., 2015). LCNEC is classified
accordingly because of its biological and clinical features.
It is included in the group of thoracic neuroendocrine
tumor per 2015 WHO classification of lung and pleural
tumors (Travis et al., 2015).
Pulmonary LCNEC may have the following features
which include (1) morphology of nesting, peripheral
palisading, and rosettes (2) expression of neuroendocrine
markers like synaptophysin, chromogranin A, TTF-1
Thyroid transcription factor, and CD56 (3) necrosis over
large zones with mitotic rates >10 per 10 high power
fields (Travis et al., 2015). Despite efforts to define these
features, diagnosis of LCNEC remains a challenge for
pathologists, especially with small biopsy specimens.
For instance, in the two prospective, single-arm clinical
trials of SCLC-like chemotherapy regimens for advanced
LCNEC, central pathology review determined 11 of 41
cases and 11 of 40 cases should be reclassified as different
diagnoses (Le Treut et al., 2013, Niho et al., 2013),
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demonstrating frequent disagreement among pathologists.
To improve diagnosis and understanding of LCNEC,
researchers investigated molecular characteristics of
LCNEC to further define its unique biologic features.
Rekhtman et al., (2016) identified that 40% of these
tumors are similar to SCLC which is characterized by p53
and RB1 gene alterations, whereas 55.5% had mutations
such as STK11/Kras that are commonly seen in NSCLC.
Moreover, 15% of LCNEC tumors showed genetic
changes in P13K/AKT/mTOR pathway; it was also
observed that LCNEC might have activating mutations
in receptor tyrosine kinase genes such as EGFR, KIT,
ERBB2 (Umemura et al., 2014, Miyoshi et al., 2017).
Although these finding do not seem very helpful in current
practice, further research into the molecular mechanisms
of LCNEC might assist oncologists in the future.
More practically, medical oncologists facing advanced
LCNEC in clinic must determine how to manage the
cases with systemic therapy. Most reports below suggest
using SCLC-based regimens in LCNEC patients. Sun
et al. (2012) revealed that advanced LCNEC could be
treated in a similar manner as SCLC rather than NSCLC
and the response rates to platinum-based chemotherapy
were 60% compared to non-platinum based chemotherapy
which was 11%, with the overall survival OS being 16.5
vs. 9.2 months in SCLC regimen and NSCLC regimen
group, respectively.
Consistent with these findings, another study
conducted by Shimada et al., (2012). observed a response
rate of 61% vs. 63% to initial chemotherapy and that
of 86% vs. 98% to chemoradiotherapy in patients high
grade LCNEC vs. SCLC, suggesting that chemotherapy
treatment using SCLC standard protocol significantly
improves the OS of patients with LCNEC compared to
that of NSCLC-based protocols.
In contrast, there are contradictory reports that do
not suggest use of SCLC-like regimens. Igawa el al.,
(2010) evaluated 14 patients with high-grade unresectable
LCNEC, with various platinum-based combination
regimens or irinotecan (SCLC-like regimen) vs.
vinorelbine or docetaxel alone (NSCLC-like regimen),
and found the objective response rate to be 50% (7/14)
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vs. 53% (41/77); one-year survival rate to be 34% vs.
48%; median survival time of 10 months vs. 12.3 months.
In keeping with this, another study conducted by
Varlotto et al., (2011) based on the data obtained from
Surveillance, Epidemiology and End Results Program
(SEER) of the US National Cancer Institute, stated that
in patients with LCNEC had characteristics where overall
survival and Lung cancer-specific survival rates were
more similar to those with other large cell carcinomas than
SCLC. Derks et al., (2017) also reported overall survival
for LCNEC patients treated with NSCLC based regimen
was significantly longer than that for those treated with
SCLC based regimen with a median survival of 8.5 vs 6.7
months, respectively. While this controversy still remains,
prognosis of advanced LCNEC remains extremely poor
regardless of treatment regimens. There is a need for novel
systemic therapies to improve poor outcomes for patients
with LCNEC.
The use of IO agents has shown promising results in
the treatment of solid tumors such as melanoma, NSCLC,
renal cell cancer; therefore, we investigated IO use in
LCNEC of the lung. Since first-line chemotherapy has
limited efficacy in LCNEC, the use of IO may become an
alternative option in the treatment of advanced LCNEC.
PD-1/PD-L1 inhibitors are proven to improve survival
in advanced stage NSCLC, and also have activity for
SCLC (Horn et al., 2018, Paz-Ares et al., 2019). Still, IO
efficacy in LCNEC is unknown and limited due to a few
case reports.
In the first case report, metastatic LCNEC in two
patients confirmed by lung biopsies were treated with
nivolumab as the sixth and third-line of treatment, showing
responses in both cases with a decrease in serum tumor
marker levels and significant tumor reduction (Daido et
al., 2017). In a second case report, a strong and robust
response to pembrolizumab was observed in a metastatic
LCNEC despite the tumor being PD-L1 negative by
immunohistochemistry (Wang et al., 2017). A third paper
reported a case of locally advanced LCNEC with complete
tumor response after palliative thoracic radiotherapy and
treatment with nivolumab, indicating that radiation may
enhance the activity of PD-1/PD/L1 inhibitors in LCNEC
(Mauclet et al., 2019).
This retrospective NCDB analysis demonstrated that
the IO group had 12 and 18-month survival of 34.0%
and 29.1% as compared to 24.1% and 15.0% in the
non-IO group. Multivariate analyses showed that female
sex, absence of liver metastasis, use of surgery, use of
chemotherapy, use of IO remained statistically significant.
Propensity score matching analysis in overall survival
showed a non-significant trend (p=0.0733) in favor of
the IO group. These findings suggest that IO treatment
benefits patients with advanced LCNEC.
We however acknowledge the limitation of current
study. This is a retrospective, “hospital-based” data
analysis using NCDB database. With lack of central
review, histologic diagnosis of LCNEC was completely
up to local pathologists. As discussed earlier, there might
be cases to which alternative diagnoses can be assigned
due to common discrepancies among pathologists.
Administration of IO agents was recorded only when they

were used as part of first course of therapy. Information
regarding regimen, dose, frequency, duration, presence of
other concurrent treatment modality was not available. It
was unknown how IO agents were obtained for treatment
such as through prospective clinical trials. The number of
cases treated with IOs was relatively small, accounting
for only 5.6% of total population. Nevertheless, the
current study includes propensity score matching and a
larger sample size than what is currently available in the
literature.
In conclusion, our findings suggest that use of IO
might improve outcomes for advanced LCNEC patients.
Further investigation is warranted to define the role of IO
treatment in advanced LCNEC.

Acknowledgements
Authors thank Mindy Flanagan for her support in
data analysis.
Authors’ contributions
Made substantial contributions to conception and
design of the study and performed data analysis and
interpretation: Komiya T;
Performed data acquisition, as well as provided
administrative, technical, and material support: Komiya T;
Manuscript preparation: all authors
Availability of data and materials
The data supporting their findings were provided by
National Cancer Database (NCDB). The data will not be
shared due to NCDB’s policy.
Financial Support and Sponsorship: not applicable
Ethical approval and consent to participate
Not applicable. This is a retrospective analysis on
anonymized data provided by NCDB. The study was
reviewed and approved by institutional review board at
Parkview Health.
Consent for Publication
Not applicable

References
Daido W, Yamasaki M, Saito N, et al (2017). Effectiveness of
Nivolumab in large cell neuroendocrine carcinoma of lung
– a report of two cases. Gan To Kagaku Ryoho, 44, 59-62
(in Japanese)
Derks JL, Jan van Suylen R, Thunnissen E, et al (2017).
Chemotherapy for pulmonary large cell neuroendocrine
carcinomas: does the regimen matter?. Eur Respir J, 49,
1601838
Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo
F (2015). Pulmonary large-cell neuroendocrine carcinoma:
from epidemiology to therapy. J Thorac Oncol, 10, 1133-41.
Horn L, Mansfield AS, Szczęsna A, et al (2018). First-line
atezolizumab plus chemotherapy in extensive-stage
small-cell lung cancer. N Engl J Med, 379, 2220-9.
Igawa S, Watanabe R, Ito I, et al (2010). Comparison of
chemotherapy for unresectable pulmonary high-grade
non-small cell neuroendocrine carcinoma and small-cell
lung cancer. Lung Cancer, 68, 438–45.
Le Treut J, Sault MC, Lena H, et al (2013). Multicentre phase
Asian Pacific Journal of Cancer Prevention, Vol 22 369

Takefumi Komiya et al
II study of cisplatin-etoposide chemotherapy for advanced
large-cell neuroendocrine lung carcinoma: the GFPC 0302
study. Ann Oncol, 24, 1548–52.
Mauclet C, Duplaquet F, Pirard L, et al (2019). Complete
tumor response of a locally advanced lung large-cell
neuroendocrine carcinoma after palliative thoracic
radiotherapy and immunotherapy with nivolumab. Lung
Cancer, 128, 53-6.
Miyoshi T, Umemura S, Matsumura Y, et al (2017). Genomic
Profiling of Large-Cell Neuroendocrine Carcinoma of the
Lung. Clin Cancer Res, 23, 757-65.
Niho S, Kenmotsu H, Sekine I, et al (2013). Combination
chemotherapy with irinotecan and cisplatin for large-cell
neuroendocrine carcinoma of the lung: a multicenter phase
II study. J Thorac Oncol, 8, 980–4.
Paz-Ares L, Dvorkin M, Chen Y, et al (2019). Durvalumab
plus platinum–etoposide versus platinum–etoposide in
first-line treatment of extensive-stage small-cell lung cancer
(CASPIAN): a randomised, controlled, open-label, phase 3
trial. Lancet, 394, 1929–39.
Rekhtman N (2010). Neuroendocrine tumors of the lung: an
update. Arch Pathol Lab Med, 134, 1628-38.
Rekhtman N, Pietanza MC, Hellmann M, et al (2016).
Next-generation sequencing of pulmonary large cell
neuroendocrine carcinoma reveals small cell carcinoma-like
and non-small cell carcinoma-like subsets. Clin Cancer Res,
22, 3618–29.
Rosenbaum PR (1989) Optimal matching for observational
studies. J Am Stat Assoc, 84, 1024-32.
Shimada Y, Niho S, Ishii G, et al (2012). Clinical features of
unresectable high-grade lung neuroendocrine carcinoma
diagnosed using biopsy specimens. Lung Cancer, 75,
368–73.
Sun JM, Ahn MJ, Ahn JS, et al (2012). Chemotherapy for
pulmonary large cell neuroendocrine carcinoma: Similar to
that for small cell lung cancer or non-small cell lung cancer?.
Lung Cancer, 77, 365– 70.
Travis WD, Bambilla E, Nicholson AG, et al (2015). The 2015
World Health Organization Classification of Lung Tumors:
Impact of Genetic, Clinical and Radiologic Advances Since
the 2004 Classification. J Thorac Oncol, 10, 1243-60.
Travis WD, Linnoila RI, Tsokos MG, et al (1991).
Neuroendocrine tumors of the lung with proposed criteria
for large-cell neuroendocrine carcinoma. An ultrastructural,
immunohistochemical, and flow cytometric study of 35
cases. Am J Surg Pathol, 15, 529-53.
Umemura S, Mimaki S, Makinoshima H, et al (2014).
Therapeutic priority of the PI3K/AKT/mTOR pathway in
small cell lung cancers as revealed by a comprehensive
genomic analysis. J Thorac Oncol, 9, 1324–31.
Varlotto JM, Medford-Davis LN, Recht A, et al (2011). Should
large cell neuroendocrine lung carcinoma be classified and
treated as a small cell lung cancer or with other large cell
carcinomas?. J Thorac Oncol, 6, 1050–8.
Wang VE, Urisman A, Albacker L, et al (2017). Checkpoint
inhibitor is active against large cell neuroendocrine
carcinoma with high tumor mutation burden. J Immunother
Cancer, 5, 75.
Zhang JT, Li Y, Yan LX, et al (2020). Disparity in clinical
outcomes between pure and combined pulmonary large cell
neuroendocrine carcinoma: A multi-center retrospective
study. Lung Cancer, 139, 118–23.

This work is licensed under a Creative Commons AttributionNon Commercial 4.0 International License.

370

Asian Pacific Journal of Cancer Prevention, Vol 22

